20 January 2017 - Public comment period now open - comments accepted until 17 February.

The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the comparative clinical effectiveness and value of 11 treatments for rheumatoid arthritis. The report, as well as accompanying draft voting questions, is now open to public comment for four weeks.

ICER is committed to engaging with all stakeholders in a thorough and transparent manner. Before completing this draft evidence report, ICER reached out to key stakeholders, including patient groups, clinical experts, and the manufacturers of the drugs to engage them in the process. 

ICER also accepted public comments on a draft scoping document prior to conducting the review. The current draft report incorporates input received from patients, clinicians, manufacturers, and other stakeholders during each of these opportunities for engagement.

Read ICER draft evidence report